NICE rejects BMS immunotherapy in advanced bladder cancer
Pharmaphorum Media Limited | July 05, 2018
Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) will not be available to advanced bladder cancer patients for at least three years in much of the UK after NICE published final guidance that rejected the drug for regular NHS funding in this use. Following its usual review process, NICE concluded in final guidance that Opdivo is not cost-effective for treating local advanced unresectable or metastatic urothelial cancer, after platinum-based chemotherapy.